dc.contributor.author | Cui, W | |
dc.contributor.author | Milner-Watts, C | |
dc.contributor.author | O'Sullivan, H | |
dc.contributor.author | Lyons, H | |
dc.contributor.author | Minchom, A | |
dc.contributor.author | Bhosle, J | |
dc.contributor.author | Davidson, M | |
dc.contributor.author | Yousaf, N | |
dc.contributor.author | Scott, S | |
dc.contributor.author | Faull, I | |
dc.contributor.author | Kushnir, M | |
dc.contributor.author | Nagy, R | |
dc.contributor.author | O'Brien, M | |
dc.contributor.author | Popat, S | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-09-06T13:07:05Z | |
dc.date.available | 2022-09-06T13:07:05Z | |
dc.date.issued | 2022-08-01 | |
dc.identifier | S0959-8049(22)00291-X | |
dc.identifier.citation | European Journal of Cancer, 2022, 171 pp. 44 - 54 | |
dc.identifier.issn | 0959-8049 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5427 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.doi | 10.1016/j.ejca.2022.05.012 | |
dc.description.abstract | BACKGROUND: Genomic sequencing is necessary for first-line advanced non-small cell lung cancer (aNSCLC) treatment decision-making. Tissue next generation sequencing (NGS) is standard but tissue quantity, quality, and time-to-results remains problematic. Here, we compare upfront cell-free-DNA (cfDNA) NGS clinical utility against routine tissue testing in patients with aNSCLC. METHODS: cfDNA-NGS was performed in consecutive, newly identified aNSCLC patients between December 2019-October 2021 alongside routine tissue genotyping. Variants were interpreted using AMP/ASCO/CAP guidelines. The primary endpoint was tier-1 variants detected on cfDNA-NGS. cfDNA-NGS results were compared to tissue results. RESULTS: Of 311 patients, 282 (91%) had an informative cfDNA-NGS test; 118 (38%) patients had a tier-1 variant identified by cfDNA-NGS. Of 243 patients with paired tissue-cfDNA tests, 122 (50%) tissue tests were informative; 85 (35%) tissue tests identified a tier-1 variant. cfDNA-NGS detected 39 additional tier-1 variants compared to tissue alone, increasing the tier-1 detection rate by 46% (from 85 to 124). The sensitivity of cfDNA-NGS relative to tissue was 75% (25% tissue tier-1 variants were not detected on cfDNA-NGS); 33% of cfDNA tier-1 variants were not identified on tissue tests. Median time from request-to-report was shorter for cfDNA-NGS versus tissue (8 versus 22 days; p < 0.0001). A total of 245 (79%) patients received first-line systemic-therapy: 49 (20%) with cfDNA-NGS results alone. Median time from sampling-to-commencement of first-line treatment was shorter for cfDNA-NGS blood draw versus first tissue biopsy (16 versus 35 days; p < 0.0001). CONCLUSIONS: cfDNA-NGS increased the tier-1 variant detection rate with high concordance with tissue, and halves time-to-treatment. 'Plasma-first' upfront cfDNA-NGS use should be considered routinely for aNSCLC. | |
dc.format | Print-Electronic | |
dc.format.extent | 44 - 54 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCI LTD | |
dc.relation.ispartof | European Journal of Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Circulating tumour DNA | |
dc.subject | Genomic sequencing | |
dc.subject | Lung cancer | |
dc.subject | Non-small cell lung cancer | |
dc.subject | Targeted therapy | |
dc.subject | Carcinoma, Non-Small-Cell Lung | |
dc.subject | Cell-Free Nucleic Acids | |
dc.subject | High-Throughput Nucleotide Sequencing | |
dc.subject | Humans | |
dc.subject | Lung Neoplasms | |
dc.subject | Mutation | |
dc.subject | United Kingdom | |
dc.title | Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-05-10 | |
dc.date.updated | 2022-09-06T12:58:47Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.ejca.2022.05.012 | |
rioxxterms.licenseref.startdate | 2022-08-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35704974 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/The Adult Drug Development Unit at the ICR and the RM | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.ejca.2022.05.012 | |
pubs.volume | 171 | |
icr.researchteam | Adult DDU ICR & RM | |
dc.contributor.icrauthor | Minchom, Anna | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-06. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S095980492200291X-main.pdf | |